University of North Carolina, Chapel Hill

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of North Carolina, Chapel Hill sits in the top decile of US sponsors by registered trial count (#28 of 15,742 sponsors by registered trial count).

1,109 total trials 108 currently recruiting 881 completed early-phase tilt top decile by trial count

University of North Carolina, Chapel Hill: 1,109 sponsored US clinical trials, 108 recruiting.

University of North Carolina, Chapel Hill sponsors 1,109 registered US clinical trials on ClinicalTrials.gov, 108 of them currently recruiting, and 881 completed. 69 of these trials are in Phase 3-4 (later-stage) and 203 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 17 trials.

Top-decile sponsor footprint

University of North Carolina, Chapel Hill ranks in the top decile of sponsors by registered trial count (#28 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 69/100

881 of 962 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,109 total, page 11 of 23

COMPLETED Phase 4

Gabapentin for Postop Pain After SSLF

NCT03123861

COMPLETED NA

Daily Step-based Exercise Using Fitness Monitors for Peripheral Artery Disease

NCT03099369

TERMINATED Phase 1

Safety and Efficacy of Fecal Microbiome Transplantation (FMT) in the Treatment of Antibiotic Dependent Pouchitis (ADP)

NCT02782325

TERMINATED Phase 3

Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy (MOMPOD)

NCT02932475

COMPLETED NA

Non-Invasive Brain Stimulation and Substance Use

NCT03122587

TERMINATED

ARDS Esophageal Balloon Pressure Changes With Positioning Study

NCT03120793

TERMINATED

Assessing Ocular Hemodynamic Response to Surgical Intervention in Glaucoma

NCT02891317

COMPLETED Phase 4

Clinical Outcomes Mandible: Buffered 1% vs. Non-Buffered 1% Lidocaine

NCT03127943

TERMINATED

Postural Changes During Right Heart Catheterization

NCT03089164

COMPLETED Phase 1

Pharmacokinetics of Apixaban in Nephrotic Syndrome

NCT02599532

COMPLETED NA

Human Biological Responses to Low Level Ozone

NCT02857283

COMPLETED NA

Cochlear Implantation in Pediatric Cases of Unilateral Hearing Loss

NCT02963974

COMPLETED

Prediction of Functional Outcomes From Chronic Critical Illness

NCT03159208

COMPLETED NA

Reducing Cardiovascular Disease Risk Factors in Rural Communities in North Carolina

NCT02707432

TERMINATED Phase 1

Evaluation of the Effect of a Nasal Allergen Challenge With Dermatophagoides Farinae Extract on Nasal Airway Inflammation in Allergic Individuals, Comparing E-cigarette Users to Cigarette Smokers and Non-smokers.

NCT03023397

COMPLETED NA

A Web-based Tailored Health Behavior Intervention for Breast and Colon Cancer Survivors (eWellness)

NCT04188002

COMPLETED NA

Reducing Postoperative Catheterization

NCT03009968

COMPLETED

Characterization of Airway Mucus in Bronchiectasis Patients and Healthy Controls

NCT03125174

COMPLETED NA

Cranial Laser Reflex Technique for Hamstring Function

NCT03044106

COMPLETED Phase 2

Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder

NCT02909959

COMPLETED Phase 4

Study of Pharmacogenomic-Guided Tacrolimus Dosing and Monitoring in Kidney Transplant Recipients

NCT03020589

COMPLETED NA

Researching the Effects of Airway Clearance Therapies in Cystic Fibrosis

NCT03078127

COMPLETED Phase 3

Nitrous Oxide for External Cephalic Version

NCT03502915

COMPLETED NA

Evaluation of a Commercial Program on Weight Loss and Health Outcomes

NCT03037567

COMPLETED NA

Geniculate Artery Embolization for the Treatment of Knee Pain

NCT02850068

TERMINATED Phase 4

The Menopause Transition: Estrogen Variability, Stress Reactivity and Mood

NCT03003949

COMPLETED NA

Use of a Novel Computerized Decision Aid for Prenatal Aneuploidy Screening

NCT02991729

COMPLETED NA

Role of Rehabilitation in Concussion Management: A Randomized Controlled Trial

NCT02988596

COMPLETED NA

High Intensity Interval Training in Osteoarthritis, Effects on Metabolomics

NCT03039452

COMPLETED

Full-arch Monolithic Zirconia ISFDP Follow up

NCT02931968

COMPLETED Phase 4

Effect of Perimenstrual Ovarian Steroid Supplementation on Perimenstrual Suicidality

NCT03720847

COMPLETED Phase 4

Large-scale Brain Organization During Cognitive Control in ADHD

NCT04349917

COMPLETED

Fecal Microbiota Transplantation (FMT) in Clostridium Difficile Infection (CDI) Not Responding to Antibiotics

NCT03117582

COMPLETED Phase 2

An Open Label Trial of Bupropion and Naltrexone for Binge Drinking

NCT02842073

COMPLETED NA

Botanical Supplement Muscle Function and Lean Body Mass

NCT03034668

COMPLETED

Sex Hormone Therapy and Mucosal Tissues

NCT02983110

COMPLETED NA

Targeting Stress Reactivity in Schizophrenia: Integrated Coping Awareness Therapy

NCT03067311

COMPLETED

Anticipated and Perceived Benefits Following Hepatitis C Treatment

NCT03000023

COMPLETED NA

Protein Supplementation Post Bariatric Surgery

NCT02951663

COMPLETED Phase 3

Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

NCT02772965

COMPLETED NA

Comparison of Two Gingival Displacement Procedures

NCT02716727

TERMINATED Phase 1

Effects of IV-Administered Ca-DTPA and Zn-DTPA To Treat Patients With Gadolinium Deposition Disease

NCT02947022

COMPLETED NA

Specialty Mental Health Probation in North Carolina

NCT02990026

COMPLETED NA

The Effects of Safety Seeking Behaviors During Exposure Therapy for Adults With Spider Phobia

NCT03233113

COMPLETED NA

Carolina Heart Alliance Networking for Greater Equity

NCT03582696

COMPLETED NA

Enhancing Patient Ability to Understand and Utilize Complex Information Concerning Medication Self-management

NCT02820038

COMPLETED Phase 2

Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure

NCT02911688

COMPLETED NA

Impact of Cigarette Pack Constituent Disclosures

NCT02785484

COMPLETED NA

Probiotics in Occupational Shift Workers

NCT02951689

COMPLETED NA

Immediate Effects of rTMS on Excitability of the Quadriceps With Knee Osteoarthritis

NCT02881775

← Previous Page 11 of 23 Next →

Phase Distribution

PhaseTrial count
Phase 1 111
Phase 2 92
Phase 3 13
Phase 4 56

What is open in the University of North Carolina, Chapel Hill pipeline

108 recruiting of 1,109 indexed (10% open); 881 completed (79%).

Phase mix: 69 late (III/IV) vs 203 early (I/II) (early-phase heavy).

Top condition: Obesity (17 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of North Carolina, Chapel Hill: open-pipeline peers nationwide

Peers matched on 1,109 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 8%10%12%14%16%18%20% Total trials Recruiting share University of North Carolina, Chapel HillUniversity of FloridaWake Forest University Health SciencesUniversity of Alabama at BirminghamNYU Langone HealthChildren's Hospitals and Clinics of MinnesotaCytokineticsSanofiOhio University
University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,109 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

What to do with this University of North Carolina, Chapel Hill page

1,109 registered trials is a research-attention snapshot, not an endorsement of University of North Carolina, Chapel Hill or any single study.

  • 108 of University of North Carolina, Chapel Hill's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition University of North Carolina, Chapel Hill studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of North Carolina, Chapel Hill pipeline card: 1,109 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.